Skip to Main Content

Stanley Szefler, M.D.
Study Designs, Biomarkers, and Endpoints in Pediatric Asthma Medication Evaluation
March 23, 2017
12:00 PM - 1:30 PM US Eastern Time
6710B Rockledge Drive, Room 1417, Bethesda, MD

Webinar Description

This lecture will review information related to the application of biomarkers for the management of asthma. This topic will include the application of biomarkers in predicting asthma exacerbations and individualizing treatment selection across asthma severity and various age groups.

Learning Objectives

  • Discuss personalized medicine as it applies to asthma management.
  • Indicate how biomarkers and patient characteristics can be used to select asthma medications.
  • Identify opportunities to prevent asthma exacerbations and manage severe asthma.

Presenter Bio

Dr. Szefler PhotoStanley J. Szefler, M.D.'s major contributions are directed toward the appropriate use of long-term control therapy in asthma, including the recognition of variability in response to asthma therapy. He has identified biomarkers and asthma characteristics that can be used to individualize asthma therapy at all levels of severity. Dr. Szefler is the Research Medical Director and Director of the Pediatric Asthma Research Program in the Breathing Institute of the Pediatric Pulmonary Section at Children’s Hospital Colorado and Professor of Pediatrics at the University of Colorado Denver School of Medicine.

Dr. Szefler is the Principal Investigator for the Denver site of the NHLBI AsthmaNet-Pediatrics Section. He has also been a member of the Expert Panel for the National Heart, Lung, and Blood Institute’s National Asthma Education and Prevention Program on “Guidelines for the Diagnosis and Management of Asthma” and a member of the Global Initiative for Asthma Science Committee and Board of Directors. Since 1997, he has been a Deputy Editor for the Journal of Allergy and Clinical Immunology.

For the past ten years, he has directed a school-centered asthma program funded by the Colorado Department of Public Health and Environment Cancer, Cardiovascular and Pulmonary Disease Program and Glaxo Smith Kline. This program seeks to define the prevalence and severity of asthma in Colorado school systems, identify those most significantly affected, establish lines of communication between schools and medical providers, and to assure that these children have state of the art asthma care. His goal is to make this program available to schools nationally with limited resources for supporting children with asthma.



Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top